Indivior PLC (LON: INDV) (“Indivior” or the “Company”) announced on 2/2/19 that it has entered into a definitive agreement to divest its rights related to the Sai Bo Song (buprenorphine, naloxone) tablet in China to Zhejiang Pukang Biotechnology Co., Ltd. (“Pukang”) for a total consideration of up to $122.5 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,